Pemvidutide vs Survodutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: ALT-801
Pemvidutide is Altimmune's once-weekly GLP-1/glucagon dual agonist, now being developed mainly for MASH (fatty liver disease with inflammation, formerly called NASH). It cleared fat out of the liver fast in trials and earned FDA Breakthrough Therapy designation, and its phase 3 trial (PERFORMA) started in August 2026. It also produced decent weight loss in an obesity trial, but it is not approved anywhere and its biggest phase 2 MASH trial missed on the fibrosis endpoint at 24 weeks.
Also: BI 456906
Survodutide is an injectable dual agonist that hits both the GLP-1 and glucagon receptors, discovered by Zealand Pharma and developed by Boehringer Ingelheim. It is being tested for obesity and for fatty liver disease (MASH), and it carries an FDA Breakthrough Therapy designation for MASH. It is still investigational and not approved for any use as of October 2026, and no US filing has been publicly announced.
Key Comparison Insights
- Pemvidutide is categorized as Metabolic, while Survodutide is Weight Loss.
Detailed Comparison
| Attribute | Pemvidutide | Survodutide |
|---|---|---|
| Category | Metabolic | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Pemvidutide activates two receptors in roughly balanced fashion. The GLP-1 side cuts appetite and slows stomach emptying, like semaglutide. The glucagon side acts directly on the liver, pushing it to burn fat and raising energy expenditure, which is why this drug class is especially interesting for fatty liver. Altimmune attaches its EuPort domain to stretch the half-life for weekly dosing and, the company says, to slow absorption for better tolerability. Glucagon activity can raise blood sugar on its own, so balancing the two signals is the design challenge. Most of the mechanism story comes from the company and is plausible, but independent data are limited. | The drug works on two fronts at once. The GLP-1 receptor arm dampens appetite, slows how fast the stomach empties, and improves blood sugar handling, the same lever that semaglutide pulls. The glucagon receptor arm is the twist: glucagon signaling raises energy expenditure and pushes the liver to burn fat rather than store it. The idea, still being proven out in trials, is that adding controlled glucagon activity to GLP-1 action burns more energy and clears liver fat faster than a GLP-1 drug alone, which is why survodutide is aimed squarely at fatty liver disease. |
| Common Dosing | 1.2-1.8 mg once weekly (MASH trial doses) Once weekly | Limited community data available See research protocols |
| Administration | Subcutaneous injection once weekly | Subcutaneous injection weekly |
| Typical Duration | 24-48 weeks in completed trials; phase 3 runs 52 weeks for the biopsy endpoint and years for outcomes | Long-term use expected |
| Best Time to Take | Same day each week | Once weekly, same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | In the phase 2 MOMENTUM obesity trial (391 adults without diabetes, 48 weeks), the 2.4 mg weekly dose produced 15.6% mean weight loss versus 2.2% on placebo, and a small MRI sub-study (50 people) found about 78% of the weight lost was fat. The focus then shifted to MASH. The phase 2b IMPACT trial randomized 212 people with biopsy-confirmed MASH and F2-F3 fibrosis to 1.2 mg, 1.8 mg or placebo. At 24 weeks, MASH resolution was 59.1% and 52.1% versus 19.1% on placebo, a strong result. But fibrosis improvement (31.8% and 34.5% versus 25.9%) was not statistically significant, and the stock fell by more than half on the news in June 2025. The 48-week data (December 2025) showed significant improvements in non-invasive fibrosis markers (ELF score and liver stiffness) and continued weight loss without a plateau, with fewer dropouts for side effects than placebo. The PERFORMA phase 3 trial (about 1,790 people, titrating to 1.8 or 2.4 mg) began in August 2026, with a 52-week biopsy readout expected in 2029. A separate phase 2 trial in alcohol use disorder (RECLAIM) reported positive topline results in July 2026. Bottom line: strong on liver fat and MASH resolution, still unproven on the fibrosis outcomes regulators care most about. | This is one of the more advanced incretin dual agonists, and the human data are real, not hypothetical. In a Phase 2 MASH trial published in the New England Journal of Medicine in 2024 (Sanyal et al.), 293 biopsy-confirmed patients got weekly survodutide or placebo for 48 weeks, and MASH improved without worsening fibrosis in 47% of the 2.4 mg group and 62% of the 4.8 mg group, versus 14% on placebo. A separate Phase 2 obesity study showed weight loss up to roughly 18.7% at 46 weeks in completers. In April 2026, Boehringer Ingelheim and Zealand Pharma reported that the Phase 3 SYNCHRONIZE-1 obesity trial hit its mark with about 16.6% average weight loss, and SYNCHRONIZE-MASLD showed about 12% weight loss versus 1% on placebo plus large drops in liver fat. Large Phase 3 MASH trials (LIVERAGE and LIVERAGE-Cirrhosis) are ongoing. The catch worth knowing: nausea, vomiting, and other GI side effects are common, as with the whole incretin class, and approval is not expected before 2027. |
Frequently Asked Questions: Pemvidutide vs Survodutide
What is the difference between Pemvidutide and Survodutide?
Pemvidutide is a metabolic peptide that pemvidutide is altimmune's once-weekly glp-1/glucagon dual agonist, now being developed mainly for mash (fatty liver disease with inflammation, formerly called nash). it cleared fat out of the liver fast in trials and earned fda breakthrough therapy designation, and its phase 3 trial (performa) started in august 2026. it also produced decent weight loss in an obesity trial, but it is not approved anywhere and its biggest phase 2 mash trial missed on the fibrosis endpoint at 24 weeks. Survodutide is a weight loss peptide that survodutide is an injectable dual agonist that hits both the glp-1 and glucagon receptors, discovered by zealand pharma and developed by boehringer ingelheim. it is being tested for obesity and for fatty liver disease (mash), and it carries an fda breakthrough therapy designation for mash. it is still investigational and not approved for any use as of october 2026, and no us filing has been publicly announced. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Pemvidutide or Survodutide?
Neither is universally "better" - the choice depends on your specific goals. Pemvidutide is typically used for metabolic purposes, while Survodutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Pemvidutide and Survodutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Pemvidutide and Survodutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.